Evidence map›Paper›PMID 41057288›Full record

Trial reportActa paediatrica (Oslo, Norway : 1992)2026

Aberrant Growth in 5-Year-Old Children After Antibiotics in the First Week of Life.

Lisanne M van Leeuwen, Gina J van Beveren, Marieke A G Peeters, Dennis Souverein, Sjoerd Euser, Debby Bogaert, Marlies A van Houten

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisanne M van LeeuwenDepartment of Paediatrics, Spaarne Hospital, Haarlem, the Netherlands.
Gina J van BeverenDepartment of Paediatrics, Spaarne Hospital, Haarlem, the Netherlands.ORCID 0000-0002-3373-804X
Marieke A G PeetersDepartment of Paediatrics, Spaarne Hospital, Haarlem, the Netherlands.
Dennis SouvereinRegional Public Health Laboratory Kennemerland, Haarlem, the Netherlands.
Sjoerd EuserRegional Public Health Laboratory Kennemerland, Haarlem, the Netherlands.
Debby BogaertDepartment of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands.
Marlies A van HoutenDepartment of Paediatrics, Spaarne Hospital, Haarlem, the Netherlands.

Funding

Chief Scientist Office SCAF/16/03Nederlandse Organisatie voor Wetenschappelijk Onderzoek 91715359Spaarne Gasthuis stimuleringsfondsZonMw 205300001
6 · The paper itself

Abstract

aimWe examined the relationship between early-life antibiotics, different regimens, and growth until age five years.

methodsData from two parallel birth cohorts were analysed: 128 healthy term-born children and 147 term-born children who received antibiotics for suspected neonatal sepsis, randomised across three regimens: Amoxicillin+Cefotaxime, Augmentin+Gentamicin, Penicillin+Gentamicin. Until age five years, growth, environmental exposures, diet, and physical activity data were collected. Primary outcomes were weight-for-age, height-for-age, and weight-for-height z-scores with early-life antibiotic exposure and the regimen as determinants of interest.

resultsThe median antibiotic exposure duration was 3 days (interquartile range 2.4-5.5 days). Children exposed to early-life antibiotics had on average 0.26 lower weight-for-height z-scores over the first five years compared to unexposed controls (p = 0.014). Especially children treated with Augmentin+Gentamicin showed lower weight-for-height z-scores, compared to unexposed controls (coefficient = 0.36; p = 0.013). Additionally, at age five years, higher birth weight percentiles were associated with higher weight-for-age, height-for-age and weight-for-height and weekly lemonade consumption was associated with higher weight-for-age z-scores.

conclusionAntibiotics in the first week of life are associated with lower weight-for-height up to age five years, with effects varying by treatment type. To explain these effects, further examination of antimicrobial-induced early-life microbiome perturbations and subsequent growth is needed.

trial registrationInternational Clinical Trial Registry Platform (https://trialsearch.who.int/): NL4882 and NL3821.

Indexed as

Anti-Bacterial AgentsChild DevelopmentGrowth DisordersBody HeightBody WeightChild, PreschoolFemaleHumansInfantInfant, NewbornMaleNeonatal SepsisAnti-Bacterial Agentsanti‐bacterial agentsgrowth and developmentneonatal early‐onset sepsis

Identifiers

PMID41057288
PMCPMC12794745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.